Results
VistaGen Therapeutics Inc.
12/22/2025 | Press release | Distributed by Public on 12/22/2025 16:29
Material Event (Form 8-K)
Item 8.01 Other Events.
On December 17, 2025, Vistagen Therapeutics, Inc. (the "Company") announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint, as measured by the least squares ("LS") mean change from baseline on the the Subjective Units of Distress Scale score for fasedienol (13.6 +/-1.54 standard error, SE) compared with placebo (14.0 +/-1.51 SE). There was no treatment difference between fasedienol and placebo for the secondary endpoints. The favorable safety data of fasedienol were consistent with previously completed clinical trials.
VistaGen Therapeutics Inc. published this content on December 22, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 22, 2025 at 22:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]